Article
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Cancer - 15 May 2024
Algazi Alain P, Moon James, Lao Christopher D, Chmielowski Bartosz, Kendra Kari L, Lewis Karl D, Gonzalez Rene, Kim Kevin, Godwin John E, Curti Brendan D, Latkovic-Taber Michaella, Lomeli Shirley H, Gufford Brandon T, Scumpia Philip O, Lo Roger S, Othus Megan, Ribas Antoni
Abstract excerpt
BACKGROUND: Aberrant PI3K/AKT signaling in BRAF-mutant cancers contributes to resistance to BRAF inhibitors. The authors examined dual MAPK and PI3K pathway inhibition in patients who had BRAF-mutated solid tumors (ClinicalTrials.gov identifier NCT01902173). METHODS: Patients with BRAF V600E/V600K-mutant solid tumors received oral dabrafenib at 150 mg twice daily with dose escalation of oral uprosertib starting...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.